Male Sexual Health Questionnaire (MSHQ) - Sexual Function Study
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
Primary:
To assess improvement in ejaculation from baseline to the end of treatment (Week 12 or
premature withdrawal) with Alfuzosin 10mg OD, using MSHQ score.
Secondary:
- To evaluate sexual function improvement
- To evaluate LUTS (Lower Uninary Tract Symptoms) improvement
- To evaluate the association between LUTS severity and sexual function.
- To assess the safety and the tolerability of Alfuzosin 10mg OD.